Latest news
Minerva Neurosciences Releases Q2 2026 Financial Results - AlphaStreetAlphaStreet · Fri, 07 Aug 2026 19:35:29 GMTMinerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary - TradingViewTradingView · Fri, 07 Aug 2026 11:41:01 GMTMinerva Neurosciences (NASDAQ: NERV) logs $107.9M loss but holds $75.4M cash - Stock TitanStock Titan · Fri, 07 Aug 2026 11:31:14 GMTMinerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M - TradingViewTradingView · Fri, 07 Aug 2026 11:23:00 GMTMinerva Neurosciences: Q2 Earnings Snapshot - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 11:20:14 GMTMinerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates - GlobeNewswireGlobeNewswire · Fri, 07 Aug 2026 11:00:00 GMTMinerva's schizophrenia trial is designed to enroll 380 patients - Stock TitanStock Titan · Fri, 07 Aug 2026 11:00:00 GMTMinerva Neurosciences (NERV) awards options tied to Phase 3 trial - Stock TitanStock Titan · Mon, 03 Aug 2026 22:05:46 GMT